Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 25;39(Pt B):174-180.
doi: 10.1016/j.nbt.2017.07.010. Epub 2017 Aug 1.

Production of virus-like particles for vaccines

Affiliations
Review

Production of virus-like particles for vaccines

J Fuenmayor et al. N Biotechnol. .

Abstract

Virus-like particles (VLPs) are nanostructures that resemble the structures of viruses. They are composed of one or more structural proteins that can be arranged in several layers and can also contain a lipid outer envelope. VLPs trigger a high humoral and cellular immune response due to their repetitive structures. A key factor regarding VLP safety is the lack of viral genomic material, which enhances safety during both manufacture and administration. Contemporary VLP production may take advantage of several systems, including bacterial, yeast, insect and mammalian cells. The choice of production platform depends on several factors, including cost and the need for post-translational modifications (PTMs), which can be essential in generating an optimal immune response. Some VLP-based vaccines designed to prevent several infectious diseases are already approved and on the market, with many others at the clinical trial or research stage. Interest in this technology has recently increased due to its advantages over classical vaccines. This paper reviews the state-of-the-art of VLP production systems and the newest generation of VLP-based vaccines now available.

Keywords: Recombinant vaccines; culture mode; immunogen; production platform; virus-like particles.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Types of vaccines: a. Live-attenuated vaccine; b. Inactivated vaccine; c. Subunit vaccines; d. Gene based vaccines; e. Virus-like particles.
Fig. 2
Fig. 2
Increase in the interest in Virus-Like Particles. Total number of publications from PubMed about VLPs.

Similar articles

Cited by

References

    1. Ulmer J.B., Valley U., Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 2006;24:1377–1383. doi: 10.1038/nbt1261. - DOI - PubMed
    1. Mäkelä P.H. Vaccines, coming of age after 200 years. FEMS Microbiol Rev. 2000;24:9–20. doi: 10.1016/S0168-6445(99)00025-X. - DOI - PubMed
    1. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014;2014:1–5. doi: 10.1073/pnas.1400472111. - DOI - PMC - PubMed
    1. Schiller J.T., Lowy D.R. Raising expectations for subunit vaccine. J Infect Dis. 2015;211:1373–1375. doi: 10.1093/infdis/jiu648. - DOI - PMC - PubMed
    1. Liu M. REVIEW DNA vaccines: a review. J Intern Med. 2003;253:402–410. doi: 10.1046/j.1365-2796.2003.01140.x. - DOI - PubMed